Business Wire

TaiwanPlus Curated Its First Film Festival to Showcase 10 Taiwanese Films Including Ang Lee’s Early Classics

Share

TaiwanPlus, a new global English-language video streaming service, has launched a Taiwan Cinema program with a selection of ten films that exemplify the diversity of Taiwan’s culture, peoples, and history. The most prominent collection is Ang Lee’s 'Father Knows Best' trilogy. Notably, this is the first time the films are available to be streamed online together. Director Lee’s strength in bringing together family members to create tension and tender comedic moments shine in this trio of PUSHING HANDS (1991), EAT DRINK MAN WOMAN (1994), and THE WEDDING BANQUET (1993).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130006205/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Taiwan+ Film Festival 2021 is on! (Photo: Business Wire)

Renowned actor Sihung Lung acts as the consummate traditional Taiwanese father in roles that evoke the sweet bitterness of an aging man trying to bring each casts’ family together. Hailed for their unrestrained portrayals of Eastern family dynamics, the collection is available for free until December 31, 2021 to global viewers outside of the United States, Canada, Mexico, Germany, and France at TaiwanPlus.com via the website’s new Cinema section and downloadable TaiwanPlus mobile app.

In addition, seven other films will be presented until December 31, 2021 that will take viewers back to some of Taiwan’s greatest films outside of the Taiwan New Cinema Wave. “Movies are the best way to convey culture and emotions. Through these ten films of different eras and themes, we provide the audience a window into Taiwan’s culture and diversity.” says Joanne Tsai, TaiwanPlus CEO.

In addition to Ang Lee’s renowned films, the program is showcasing films directed by Chung Mong-hong, who recently won Best Narrative Feature and Best Original Screenplay for THE FALLS (2021) at this year's Golden Horse Awards. The After Death duo that brings us to edgier contemporary Taiwanese films that dare to dive into darker narratives. THE FOURTH PORTRAIT (2010) follows the story of a son left behind after the death of his father while in SOUL (2013), the mysterious collapse of a young chef leads to a terrifying spiritual possession in the mountains.

A trio of restored films include two cult favorite black and white films from the Taiwan Hollywood era of the 1960s-- THE FANTASY OF DEER WARRIOR (1961) and VENGEANCE OF THE PHOENIX SISTERS (1968) along with WHEEL OF LIFE (1983), an anthology helmed by King Hu that features three main characters reincarnating into the same twisted love triangle in each segment.

Rounding out the series are two documentaries. In SMALL TALK (2016) by Huang Hui-chen, a 20 year film in the making where the filmmaker attempts to confront and reconcile painful past memories with her mother, a lesbian Taoist priestess. Meanwhile, in ARCHIVING TIME (2019), viewers follow a group of film preservation staff from the Taiwan Film and Audiovisual Institute as they work to preserve crumbling reels of film the world has yet to see.

Watch Free @https://tw.plus/twxgh

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Vicky Hsu
pr@taiwanplus.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 09:00:00 EET | Press release

Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approaches for combating cancer. IDEAL Japan follows the conclusion of the highly respected JCA (Japanese Cancer Association) Mauvernay Award in Japan, which honored Japanese scientists over the last 20 years, from 2004 through 2024. Debiopharm is now transitioning its historic award into the IDEAL Japan initiative aiming to accelerate preclinical scientific research that could give rise to new treatments for cancer patients. “Our vision is to collaborate to find a cure for cancer,”explained Thierry Mauvernay, President of Debiopharm. “We believe that our ongoing Swiss-Japanese connection needs to evolve and catalyze the trans

Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 08:00:00 EET | Press release

Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117345890/en/ Adam Plich, Founder and CEO of Avanzanite. The announcement follows a record-breaking Q3 2025 for Avanzanite, with revenue tripling year-on-year and climbing over 20% quarter-on-quarter. This strategic funding will accelerate the expansion of Avanzanite’s pan-European infrastructure and propel both current and future rare disease product launches. The capital will also enable Avanzanite to form new strategic alliances and acquire assets to expand its portfolio. Avanzanite was built to solve Europe’s rare-disease medicines access gap. Under one pan-European operation, Avanzanite brings toget

Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 05:35:00 EET | Press release

Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through its partners by the end of October 2025, marking a threefold increase compared to the same period in 2024, with MSMEs among the key segments driving this growth. International Finance Corporation estimates a US$8 trillion financing gap for MSMEs in emerging markets and developing economies. With global platforms, from e-commerce to food delivery, entering emerging markets and local platforms in these markets continue to scale, many are looking to offer tailored credit services to better support MSMEs operating on their ecosystems. Doin

Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 05:00:00 EET | Press release

Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in real-time global treasury management. It has already supported a successful H

Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo ™ 300mg18.11.2025 04:51:00 EET | Press release

The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These improvements may contribute to an enhanced treatment journey for patients by helping reduce the disease burden they face throughout their care. Given its distinctive product profile, Omlyclo™ 300mg has the potential to become an

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye